Sabo E - Search Results

1

Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring.

Perets R, Greenberg O, Shentzer T, Semenisty V, Epelbaum R, Bick T, Sarji S, Ben-Izhak O, Sabo E, Hershkovitz D. Perets R, et al. Among authors: sabo e. Oncologist. 2018 May;23(5):566-572. doi: 10.1634/theoncologist.2017-0467. Epub 2018 Jan 25. Oncologist. 2018. PMID: 29371474 Free PMC article.

2

LNA-based PCR clamping enrichment assay for the identification of KRAS mutations.

Efrati E, Elkin H, Peerless Y, Sabo E, Ben-Izhak O, Hershkovitz D. Efrati E, et al. Among authors: sabo e. Cancer Biomark. 2010-2011;8(2):89-94. doi: 10.3233/CBM-2011-0203. Cancer Biomark. 2010. PMID: 21896996

3

Molecular morphometric analysis shows relative intra-tumoural homogeneity for KRAS mutations in colorectal cancer.

Farber L, Efrati E, Elkin H, Peerless Y, Sabo E, Ben-Izhak O, Hershkovitz D. Farber L, et al. Among authors: sabo e. Virchows Arch. 2011 Nov;459(5):487-93. doi: 10.1007/s00428-011-1158-y. Epub 2011 Oct 21. Virchows Arch. 2011. PMID: 22016105

4

Adenoma and carcinoma components in colonic tumors show discordance for KRAS mutation.

Hershkovitz D, Simon E, Bick T, Prinz E, Noy S, Sabo E, Ben-Izhak O, Vieth M. Hershkovitz D, et al. Among authors: sabo e. Hum Pathol. 2014 Sep;45(9):1866-71. doi: 10.1016/j.humpath.2014.05.005. Epub 2014 May 28. Hum Pathol. 2014. PMID: 24998492

5

Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions.

Nagawkar SS, Abu-Funni S, Simon E, Bick T, Prinz E, Sabo E, Ben-Izhak O, Hershkovitz D. Nagawkar SS, et al. Among authors: sabo e. Pancreas. 2016 Jul;45(6):876-81. doi: 10.1097/MPA.0000000000000562. Pancreas. 2016. PMID: 26646269

6

Variation in KRAS driver substitution distributions between tumor types is determined by both mutation and natural selection.

Ostrow SL, Simon E, Prinz E, Bick T, Shentzer T, Nagawkar SS, Sabo E, Ben-Izhak O, Hershberg R, Hershkovitz D. Ostrow SL, et al. Among authors: sabo e. Sci Rep. 2016 Feb 23;6:21927. doi: 10.1038/srep21927. Sci Rep. 2016. PMID: 26902163 Free PMC article.

7

Clinically significant sub-clonality for common drivers can be detected in 26% of KRAS/EGFR mutated lung adenocarcinomas.

Simon E, Bick T, Sarji S, Shentzer T, Prinz E, Yehiam L, Sabo E, Ben-Izhak O, Hershkovitz D. Simon E, et al. Among authors: sabo e. Oncotarget. 2017 Jul 11;8(28):45736-45749. doi: 10.18632/oncotarget.17399. Oncotarget. 2017. PMID: 28501852 Free PMC article.

8

Characterization of Factors Affecting the Detection Limit of EGFR p.T790M in Circulating Tumor DNA.

Fahoum I, Forer R, Volodarsky D, Vulih I, Bick T, Sarji S, Bamberger Z, Ben-Izhak O, Sabo E, Hershberg R, Hershkovitz D. Fahoum I, et al. Among authors: sabo e. Technol Cancer Res Treat. 2018 Jan 1;17:1533033818793653. doi: 10.1177/1533033818793653. Technol Cancer Res Treat. 2018. PMID: 30099961 Free PMC article.

9

Development of a computerized morphometry application for assessment of the tumor fraction in colon carcinoma tissue samples.

Hershkovitz T, Shenhav A, Sabo E, Ben-Izhak O, Hershkovitz D. Hershkovitz T, et al. Among authors: sabo e. Appl Immunohistochem Mol Morphol. 2013 Jan;21(1):54-8. doi: 10.1097/PAI.0b013e318256d9bd. Appl Immunohistochem Mol Morphol. 2013. PMID: 22595946

10

Normal colon tissue and colon carcinoma show no difference in heparanase promoter methylation.

Peerless Y, Simon E, Sabo E, Ben-Izhak O, Hershkovitz D. Peerless Y, et al. Among authors: sabo e. Exp Mol Pathol. 2013 Apr;94(2):309-13. doi: 10.1016/j.yexmp.2013.01.001. Epub 2013 Jan 10. Exp Mol Pathol. 2013. PMID: 23313782

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

326 results

Search Page

Filters